Aeovian Pharmaceuticals

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel, highly selective therapeutics that inhibit the mTORC1 pathway. Their lead candidate, AV078, is a first-in-class mTORC1 inhibitor for treating seizures associated with Tuberous Sclerosis Complex (TSC). The company aims to address unmet medical needs in rare neurological and age-related diseases.

Buy Funded Startups lists

Funding Round:

Funding Amount: $50M

Date: 28-Mar-2024

Investors: Hevolution, Apollo Health Ventures, Sofinnova Investments, venBio, Evotec, b2venture

Markets: Biotechnology, Pharmaceuticals, Neurology, Biopharma, Health Care

HQ: Berkeley, California, United States

Founded: 2012

Website: https://www.aeovian.com/

LinkedIn: https://www.linkedin.com/company/aeovian-pharmaceuticals

Twitter:

Instagram: